ECSP11011210A - Sal de hemi-fumarato del ácido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxílico - Google Patents

Sal de hemi-fumarato del ácido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxílico

Info

Publication number
ECSP11011210A
ECSP11011210A EC2011011210A ECSP11011210A ECSP11011210A EC SP11011210 A ECSP11011210 A EC SP11011210A EC 2011011210 A EC2011011210 A EC 2011011210A EC SP11011210 A ECSP11011210 A EC SP11011210A EC SP11011210 A ECSP11011210 A EC SP11011210A
Authority
EC
Ecuador
Prior art keywords
etil
hemi
azetidin
imino
trifluoro
Prior art date
Application number
EC2011011210A
Other languages
English (en)
Inventor
Caspar Vogel
Michael Mutz
Piotr Karpinski
Ricardo Schneeberger
Lech Ciszewski
La Cruz Marilyn De
Christian Riegert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11011210A publication Critical patent/ECSP11011210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a una sal de hemi-fumarato del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico (Compuesto I), a composiciones farmacéuticas que comprenden esta sal, a procesos para formar esta sal, y a su uso en un tratamiento médico. En adición, la presente invención también se refiere a nuevas formas polimórficas de la forma de sal de hemi-fumarato del Compuesto I, así como a composiciones farmacéuticas que comprenden estas formas polimórficas, a procesos para obtenerlas, y a su uso en un tratamiento médico.
EC2011011210A 2008-12-18 2011-07-15 Sal de hemi-fumarato del ácido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxílico ECSP11011210A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20305308P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
ECSP11011210A true ECSP11011210A (es) 2011-08-31

Family

ID=42236293

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011210A ECSP11011210A (es) 2008-12-18 2011-07-15 Sal de hemi-fumarato del ácido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxílico

Country Status (36)

Country Link
US (6) US20120115840A1 (es)
EP (2) EP2676953B1 (es)
JP (1) JP5627597B2 (es)
KR (5) KR101885052B1 (es)
CN (2) CN102256943A (es)
AR (3) AR074694A1 (es)
AU (1) AU2009335924B2 (es)
BR (1) BRPI0923176B8 (es)
CA (2) CA2951479A1 (es)
CL (1) CL2011001490A1 (es)
CO (1) CO6390104A2 (es)
CY (2) CY1114662T1 (es)
DK (2) DK2379497T3 (es)
EC (1) ECSP11011210A (es)
ES (2) ES2436197T3 (es)
HK (1) HK1159631A1 (es)
HR (2) HRP20131106T1 (es)
HU (1) HUE034819T2 (es)
IL (3) IL294514A (es)
JO (1) JO2894B1 (es)
LT (1) LT2676953T (es)
MA (1) MA32961B1 (es)
MX (1) MX2011006609A (es)
MY (1) MY152669A (es)
NZ (1) NZ593061A (es)
PE (2) PE20142374A1 (es)
PL (2) PL2676953T3 (es)
PT (2) PT2379497E (es)
RS (2) RS56110B1 (es)
RU (1) RU2518114C3 (es)
SG (1) SG171785A1 (es)
SI (2) SI2379497T1 (es)
TW (2) TWI591055B (es)
UY (1) UY32330A (es)
WO (1) WO2010080409A1 (es)
ZA (1) ZA201103709B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
AU2015246036A1 (en) * 2014-04-10 2016-10-13 Novartis Ag S1P modulator immediate release dosage regimen
WO2015155711A1 (en) 2014-04-10 2015-10-15 Novartis Ag Immunosuppressant formulation
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20190047951A1 (en) 2016-01-04 2019-02-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2018341136A1 (en) * 2017-09-27 2020-03-12 Novartis Ag Parenteral formulation comprising siponimod
US11390583B2 (en) 2017-09-27 2022-07-19 Dr. Reddy's Laboratories Limited Process for preparation of Siponimod, its salts and solid state forms thereof
MX2020007326A (es) * 2017-09-29 2020-09-07 Novartis Ag Regimen de dosificacion de siponimod.
RU2020114750A (ru) 2017-09-29 2021-10-29 Новартис Аг Схема введения доз сипонимода
EP3743405B1 (en) 2018-01-22 2023-11-15 Teva Pharmaceuticals International GmbH Crystalline siponimod fumaric acid and polymorphs thereof
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020161632A1 (en) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Crystalline solid forms of siponimod
US20220144768A1 (en) * 2019-02-27 2022-05-12 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
EP3972954A1 (en) 2019-05-21 2022-03-30 Synthon B.V. Siponimod maleic acid and fumaric acid salt
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021240547A2 (en) * 2020-05-29 2021-12-02 Cipla Limited Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forms thereof
WO2022064007A1 (en) 2020-09-25 2022-03-31 Synthon B.V. Siponimod salts and cocrystals
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (zh) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 一种羧酸类化合物半富马酸盐的晶型及其制备方法
WO2022199865A1 (en) 2021-03-26 2022-09-29 Olon S.P.A. Novel crystalline compound of siponimod hemifumarate
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
ATE124217T1 (de) * 1991-06-04 1995-07-15 Fujisawa Pharmaceutical Co Vorbeugende/therapeutische zusammensetzung für die pleuropneumonie des schweins.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
SK285035B6 (sk) 1992-10-28 2006-05-04 Genentech, Inc. Antagonisty rastového faktora vaskulárnych endotelových buniek
DE69430575T2 (de) * 1993-06-08 2002-10-02 Hisamitsu Pharmaceutical Co Iontophoretisches system
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69725585T2 (de) * 1996-04-04 2004-07-01 Sankyo Co., Ltd. Phenylalkylcarbonsäure-derivate
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1140173B2 (en) 1998-12-22 2013-04-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
WO2002053538A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Amlodipine fumarate
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20030216376A1 (en) * 2002-03-20 2003-11-20 Revital Lifshitz-Liron Crystalline forms of quetiapine hemifumarate
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004110330A1 (en) 2003-06-13 2004-12-23 Stephen Dichiera Adjustable bed support and bed
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP2359821A1 (en) * 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
CN101238099A (zh) * 2005-08-04 2008-08-06 诺瓦提斯公司 维格列汀的盐
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PE20121179A1 (es) * 2006-11-07 2012-09-13 Novartis Ag Forma cristalina de hemifumarato de alisquireno

Also Published As

Publication number Publication date
MY152669A (en) 2014-10-31
LT2676953T (lt) 2017-06-26
US20120115840A1 (en) 2012-05-10
RS56110B1 (sr) 2017-10-31
TW201509909A (zh) 2015-03-16
HRP20131106T1 (hr) 2013-12-20
KR101885052B1 (ko) 2018-08-02
TWI591055B (zh) 2017-07-11
US20210323915A1 (en) 2021-10-21
EP2676953B1 (en) 2017-03-22
BRPI0923176A8 (pt) 2017-09-12
US20150175536A1 (en) 2015-06-25
NZ593061A (en) 2013-08-30
KR20170062554A (ko) 2017-06-07
PL2379497T3 (pl) 2014-01-31
AR121635A2 (es) 2022-06-22
HUE034819T2 (en) 2018-02-28
EP2379497A1 (en) 2011-10-26
CN104803902A (zh) 2015-07-29
AU2009335924A1 (en) 2011-06-30
ZA201103709B (en) 2012-01-25
DK2676953T3 (en) 2017-07-03
PT2676953T (pt) 2017-06-29
BRPI0923176B8 (pt) 2021-05-25
CO6390104A2 (es) 2012-02-29
PE20120336A1 (es) 2012-04-30
KR20110096584A (ko) 2011-08-30
DK2379497T3 (da) 2013-11-25
IL213071A0 (en) 2011-07-31
PL2676953T3 (pl) 2017-09-29
TWI500603B (zh) 2015-09-21
IL294514A (en) 2022-09-01
AU2009335924B2 (en) 2012-11-08
SI2379497T1 (sl) 2013-12-31
CA2747437C (en) 2018-08-21
JP2012512881A (ja) 2012-06-07
JP5627597B2 (ja) 2014-11-19
CA2951479A1 (en) 2010-07-15
CL2011001490A1 (es) 2012-01-13
WO2010080409A1 (en) 2010-07-15
RU2518114C2 (ru) 2014-06-10
ES2436197T3 (es) 2013-12-27
ES2631203T3 (es) 2017-08-29
PE20142374A1 (es) 2015-01-30
US20220402870A1 (en) 2022-12-22
EP2379497B1 (en) 2013-08-21
HK1159631A1 (es) 2012-08-03
CY1114662T1 (el) 2016-10-05
US20140005162A1 (en) 2014-01-02
MA32961B1 (fr) 2012-01-02
US20180118678A1 (en) 2018-05-03
BRPI0923176B1 (pt) 2020-12-01
SG171785A1 (en) 2011-07-28
RU2011129222A (ru) 2013-01-27
AR112227A2 (es) 2019-10-02
CA2747437A1 (en) 2010-07-15
IL253845A0 (en) 2017-09-28
PT2379497E (pt) 2013-11-29
RU2518114C3 (ru) 2021-11-24
KR20160129915A (ko) 2016-11-09
UY32330A (es) 2010-07-30
HRP20170916T1 (hr) 2017-09-22
IL253845B (en) 2022-08-01
US20230357142A9 (en) 2023-11-09
CY1119037T1 (el) 2018-01-10
AR074694A1 (es) 2011-02-02
RS53041B (en) 2014-04-30
EP2676953A1 (en) 2013-12-25
BRPI0923176A2 (pt) 2016-02-16
MX2011006609A (es) 2011-06-30
SI2676953T1 (sl) 2017-07-31
CN102256943A (zh) 2011-11-23
KR20160064245A (ko) 2016-06-07
TW201035048A (en) 2010-10-01
KR20180006492A (ko) 2018-01-17
JO2894B1 (en) 2015-09-15

Similar Documents

Publication Publication Date Title
AR121635A2 (es) Nueva sal y formas cristalinas
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
CR20110611A (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil) acetato de 4-(dimetilamino)butilo
CU20150062A7 (es) Lactamas n-(heteroarilo sustituido) fusionadas utiles en el tratamiento del crecimiento celular anormal
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
EA201071144A1 (ru) Гетероциклические производные
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CR20120296A (es) Nuevos compuestos de espiropiperidina
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
CR20110269A (es) Lactamas como inhibidores de beta secretasa
UY31627A1 (es) Nuevas formas cristalinas del ácido 4-[4-(2-adamantilcarbamoíl)-5-ter-butil-pirazol-1-il]benzoico
CO6741154A2 (es) Compuestos de triazolopiridina
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
CY1124505T1 (el) Κρυσταλλικες μορφες βιλαστινης και μεθοδοι παρασκευης αυτων
ECSP11011323A (es) Método o sistema que usa biomarcadores para el seguimiento de un tratamiento.
HN2010002408A (es) Sal de difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-((1-(n-metilcarbamoilmetil)piperidin-4-il)oxi)quinazolina
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
ES2403130R1 (es) Forma polimorfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparacion
BRPI0908509A2 (pt) Formas de sal de um derivado de 6-flúor-1, 2-di-hidro-2-oxo-3h-indol-3-ilideno, processo para a produção das mesmas e composições farmacêuticas contendo as mesmas
CY1120307T1 (el) Καινοφανεις ενωσεις επιλεκτικων ανταγωνιστων του υποδοχεα νκ-3, φαρμακευτικες συνθεσεις και μεθοδοι χρησης σε διαμεσολαβουμενες απο υποδοχεις νκ-3 διαταραχες